Pharmaceutical Israel’s Teva Pharmaceutical Industries and Heptares Therapeutics, a wholly-owned subsidiary of Sosei Group have entered into a licensing and drug-discovery agreement under which Teva will receive exclusive global rights to develop, manufacture and commercialize novel, small-molecule calcitonin gene-related peptide (CGRP) antagonists. 25 November 2015